Publications

Human Immunodeficiency Virus (HIV) infection presents a multifaceted challenge, extendingbeyond its primary impact on the immune system to affect various organ systems. Amongthese, the bone marrow, the primary site for hematopoiesis, undergoes substantialalterations during HIV infection, profoundly influencing erythropoiesis—the process of redblood cell production. Anemia, a prevalent hematologic complication in HIV-infectedindividuals, often serves as a marker of disease progression and impacts overall healthoutcomes. This paper aims to delve into the intricate relationship between HIV-associatedbone marrow alterations and their consequential effects on erythropoiesis. The mechanismsunderlying bone marrow changes in HIV infection, including direct viral effects,dysregulation of cytokine networks, and inflammatory processes, significantly disrupt thedelicate balance necessary for efficient erythropoiesis. The impact of these alterations onerythropoiesis manifests through ineffective red blood cell production, decreasederythropoietin responsiveness, and shortened red blood cell lifespan. Chronic inflammationfurther complicates erythropoietic processes, contributing to the development andperpetuation of anemia in HIV-infected individuals. Therapeutic interventions encompass amultifaceted approach, including antiretroviral therapy (ART) to control viral replication,erythropoiesis-stimulating agents, and adjunctive nutritional support to manage anemia.However, emerging research targeting bone marrow microenvironmental factors and novelagents stimulating erythropoiesis offer promising avenues for future therapeuticdevelopment.Keywords: HIV, bone marrow, erythropoiesis, erythropoietin, antiretroviral therapy